A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Completed · Phase 2

Conditions studied: Pancreatic Cancer, Carcinoma, Pancreatic Ductal, Pancreatic Disease

In brief

The purpose of this study is to continue the safety and immunogenicity of AGS-1C4D4 administered in combination with gemcitabine in subjects previously treated in protocol 2008002.

Key facts

Study ID

NCT01608711

Run by

Agensys, Inc.

People needed

2

Starts

2012-08-07

Expected to finish

2015-11-16

Last updated by the study team

2017-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has stable disease or better per Response Evaluation Criteria in Solid Tumors (RECIST) criteria v.1.1. in Protocol 2008002

You may not qualify if…

• More than 6 weeks (2 doses) has lapsed from the time of the last infusion in AGS-1C4D4 Protocol 2008002
• Use of the following prohibited medications / therapies:
• Monoclonal antibody therapy, other than AGS-1C4D4
• Chemotherapy, other than gemcitabine
• Investigational therapy other than AGS-1C4D4
• Erlotinib (Tarceva)
• Any clinical condition which would not allow safe conduct of this study

Where it is running

• Site US116 — Madison, Wisconsin, United States
• Site CA00203 — Toronto, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.